Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

An intermediate effect size variant in UMOD confers risk for chronic kidney disease

View ORCID ProfileEric Olinger, Céline Schaeffer, Kendrah Kidd, Yurong Cheng, Inès Dufour, Guglielmo Schiano, Holly Mabillard, Elena Pasqualetto, Elhussein A. E. Elhassan, Patrick Hofmann, Daniel G. Fuster, Andreas D. Kistler, Peter J. Conlon, Ian J. Wilson, Stanislav Kmoch, Genomics England Research Consortium, Kai-Uwe Eckardt, Anthony J. Bleyer Sr., Anna Köttgen, Michael Wiesener, View ORCID ProfileJohn A. Sayer, Luca Rampoldi, Olivier Devuyst
doi: https://doi.org/10.1101/2021.09.27.21263789
Eric Olinger
1Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland
2Translational and Clinical Research Institute, Newcastle University, NE1 3BZ Newcastle upon Tyne, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric Olinger
  • For correspondence: eric.olinger@ncl.ac.uk olivier.devuyst@uzh.ch
Céline Schaeffer
3Molecular Genetics of Renal Disorders, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kendrah Kidd
4Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, 27101 NC
5Department of Paediatrics and Adolescent Medicine, Charles University, 128 08 Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yurong Cheng
6Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, D 79106 Freiburg, Germany
16Faculty of Biology, University of Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inès Dufour
1Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland
7Division of Nephrology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guglielmo Schiano
1Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly Mabillard
8Renal Services, Newcastle Upon Tyne Hospitals National Health Service Trust, NE7 7DN, Newcastle upon Tyne, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Pasqualetto
3Molecular Genetics of Renal Disorders, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elhussein A. E. Elhassan
9Division of Nephrology, Beaumont General Hospital, 1297 Dublin, Republic of Ireland and Department of Medicine, Royal College of Surgeons in Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Hofmann
1Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel G. Fuster
10Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas D. Kistler
11Department of Medicine, Cantonal Hospital Frauenfeld, 8501 Frauenfeld, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter J. Conlon
9Division of Nephrology, Beaumont General Hospital, 1297 Dublin, Republic of Ireland and Department of Medicine, Royal College of Surgeons in Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian J. Wilson
12Biosciences Institute, Newcastle University, Central Parkway, NE1 3BZ Newcastle upon Tyne, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanislav Kmoch
4Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, 27101 NC
5Department of Paediatrics and Adolescent Medicine, Charles University, 128 08 Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai-Uwe Eckardt
13Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
14Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony J. Bleyer Sr.
4Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, 27101 NC
5Department of Paediatrics and Adolescent Medicine, Charles University, 128 08 Prague, Czech Republic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Köttgen
6Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of Freiburg, D 79106 Freiburg, Germany
17CIBSS - Centre for Integrative Biological Signalling Studies, University of Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Wiesener
14Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Sayer
2Translational and Clinical Research Institute, Newcastle University, NE1 3BZ Newcastle upon Tyne, United Kingdom
8Renal Services, Newcastle Upon Tyne Hospitals National Health Service Trust, NE7 7DN, Newcastle upon Tyne, UK
15NIHR Newcastle Biomedical Research Centre, NE4 5PL Newcastle upon Tyne, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John A. Sayer
Luca Rampoldi
3Molecular Genetics of Renal Disorders, Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Devuyst
1Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland
7Division of Nephrology, Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: eric.olinger@ncl.ac.uk olivier.devuyst@uzh.ch
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

The kidney-specific gene UMOD encodes for uromodulin, the most abundant protein excreted in normal urine. Rare, large-effect variants in UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD) while common, low-effect variants strongly associate with kidney function and risk of chronic kidney disease (CKD) in the general population. It is unknown whether intermediate-effect variants in UMOD contribute to CKD. Here, candidate intermediate-effect UMOD variants were identified using large population and ADTKD cohorts. Biological and phenotypical effects were investigated using cell models, in silico simulations and international databases and biobanks. Eight UMOD missense variants reported in ADTKD are present in gnomAD with MAF ranging from 10−5 to 10−3. Among them, the missense variant p.Thr62Pro is detected in ∼1/1,000 individuals of European ancestry, shows incomplete penetrance but a high genetic load in familial clusters of CKD and is associated with kidney failure in the 100,000 Genomes Project (OR 3.99; 1.84-8.98) and the UK Biobank (OR 4.12; 1.32-12.85). Compared to canonical ADTKD mutations, the p.Thr62Pro carriers displayed reduced disease severity, with slower progression of CKD, intermediate reduction of urinary UMOD levels, in line with an intermediate trafficking defect in vitro. Identification of an intermediate-effect UMOD variant completes the spectrum of UMOD-associated kidney diseases and provides novel insights into the mechanisms of ADTKD and the genetic architecture of CKD.

Significance Statement The genetic architecture of chronic kidney disease (CKD) remains incompletely understood. Variants in the kidney-specific gene UMOD cause autosomal dominant tubulointerstitial kidney disease (ADTKD) and are associated with kidney function and risk of CKD in the general population. Here, we identified an intermediate-effect variant, p.Thr62Pro, detected in ∼1:1,000 individuals of European ancestry, that showed a high genetic load in familial clusters of CKD and was associated with an OR of ∼4 for kidney failure in the 100,000 Genomes Project and the UK Biobank. Compared to canonical ADTKD mutations, p.Thr62Pro carriers displayed reduced disease severity and an intermediate trafficking defect. These findings complete the spectrum of UMOD-associated kidney diseases and provide a paradigm for the genetic contribution to CKD.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

EO is supported by an Early Postdoc Mobility-Stipendium of the Swiss National Science Foundation (P2ZHP3_195181) and a Kidney Research UK grant Paed_RP_001_20180925, the Fonds National de la Recherche Luxembourg (grant 6903109) and the University Research Priority Program "Integrative Human Physiology, ZIHP" of the University of Zurich. MW is supported by Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 387509280 - SFB 1350, TP C4. The work of AK was supported by German Research Foundation (DFG) grant KO 3598/5-1, DFG - Project-ID 431984000 - SFB 1453. ADK was supported by a grant from the University of Zurich (Forschungskredit FK-14-035). EAEE is funded by the Royal College of Surgeons in Ireland Blackrock Clinic StAR MD. OD is supported by the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 860977, the European Reference Network for Rare Kidney Diseases (project 739532), the Swiss National Science Foundation's National Center of Competence in Research Kidney Control of Homeostasis program, the Swiss National Science Foundation (grant 310030-189044, the Gebert-Ruef Foundation for research on ADTKD-UMOD and the University Research Priority Program (URPP) ITINERARE at the University of Zurich. KK, SK and AJB were supported by grant NU21-07-00033 from the Ministry of Health of the Czech Republic. LR is supported by the Italian Ministry of Health (RF-2010-2319394 and RF-2016-02362623). JAS is supported by Kidney Research UK and the Northern Counties Kidney Research Fund. The 100,000 Genomes Project is funded by the National Institute for Health Research and NHS England. The Wellcome Trust, Cancer Research UK and the Medical Research Council have also funded research infrastructure. UK Biobank is supported by its founding funders the Wellcome Trust and UK Medical Research Council, as well as the Department of Health, Scottish Government, the Northwest Regional Development Agency, British Heart Foundation and Cancer Research UK. The GCKD study was funded by the German Ministry of Research and Education (Bundesminsterium fuer Bildung und Forschung, BMBF, grant number 01ER0804, K.U.E.); by the Foundation KfH Stiftung Praeventivmedizin and by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - Projektnummer 246781735 - SFB 1140; and by grants provided by Bayer, Fresenius Medical Care and Amgen. Genotyping was supported by Bayer Pharma AG. uUMOD measurements in GCKD were supported by the Swiss National Centre of Competence in Research Kidney Control of Homeostasis program and the Swiss National Science Foundation grant 310030_189044.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Informed and written consent was obtained from all participants and individual-level data was de-identified. All methods were carried out in accordance with approved guidelines and the Declaration of Helsinki. The 100,000 Genomes research and clinical project model and its informed consent process has been approved by the United Kingdom National Research Ethics Service Research Ethics Committee for East of England - Cambridge South Research Ethics Committee (https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/)(Ref 14/EE/1112). Ethics approval for the UK Biobank study was obtained from the United Kingdom North West Centre for Research Ethics Committee (approval number 11/NW/0382) (https://www.ukbiobank.ac.uk/). The German Chronic Kidney Disease Cohort was approved by the ethics commission of the Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Germany (Nr 3831) and by the ethics committees of all participating institutions and registered in the national registry for clinical studies (Deutsches Register Klinischer Studien 00003971) (https://www.gckd.de/). The ADTKD cohort study was approved by the institutional review board of the Wake Forest School of Medicine, North Carolina, USA (Wake Forest University Health Sciences IRB00000352 "Characteristics of Individuals with Inherited Kidney Disease"), the Institutional review board of the Universite Catholique de Louvain (UCL) Medical School and Saint Luc University Hospital, Belgium (2011/04MAI/184) and the European Community's Seventh Framework Program "European Consortium for High-Throughput Research in Rare Kidney Diseases (EURenOmics)" Ethics Advisory Board. Further institutions involved in human participant research received local IRB approval as detailed in Table S8.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵18 List of authors and their affiliations appears in the supplementary information

  • Competing Interest Statement: The authors declare no potential conflict of interest relevant to this article.

Data Availability

The data that support the findings of this study are available from the article and the supplementary files, through The Human Gene Mutation Database at http://www.hgmd.cf.ac.uk/ac/index.php and PubMed at https://pubmed.ncbi.nlm.nih.gov. Data presented here were derived from the following resources available in the public domain: The Genome Aggregation Database v2.1.1 (https://gnomad.broadinstitute.org/) and Ensembl (release 100): (https://www.ensembl.org/index.html).

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
An intermediate effect size variant in UMOD confers risk for chronic kidney disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
An intermediate effect size variant in UMOD confers risk for chronic kidney disease
Eric Olinger, Céline Schaeffer, Kendrah Kidd, Yurong Cheng, Inès Dufour, Guglielmo Schiano, Holly Mabillard, Elena Pasqualetto, Elhussein A. E. Elhassan, Patrick Hofmann, Daniel G. Fuster, Andreas D. Kistler, Peter J. Conlon, Ian J. Wilson, Stanislav Kmoch, Genomics England Research Consortium, Kai-Uwe Eckardt, Anthony J. Bleyer Sr., Anna Köttgen, Michael Wiesener, John A. Sayer, Luca Rampoldi, Olivier Devuyst
medRxiv 2021.09.27.21263789; doi: https://doi.org/10.1101/2021.09.27.21263789
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
An intermediate effect size variant in UMOD confers risk for chronic kidney disease
Eric Olinger, Céline Schaeffer, Kendrah Kidd, Yurong Cheng, Inès Dufour, Guglielmo Schiano, Holly Mabillard, Elena Pasqualetto, Elhussein A. E. Elhassan, Patrick Hofmann, Daniel G. Fuster, Andreas D. Kistler, Peter J. Conlon, Ian J. Wilson, Stanislav Kmoch, Genomics England Research Consortium, Kai-Uwe Eckardt, Anthony J. Bleyer Sr., Anna Köttgen, Michael Wiesener, John A. Sayer, Luca Rampoldi, Olivier Devuyst
medRxiv 2021.09.27.21263789; doi: https://doi.org/10.1101/2021.09.27.21263789

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9758)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2304)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1554)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11634)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2140)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2173)
  • Public and Global Health (4648)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)